Pancreatic Cancer Research

ResearcherIshikawa Prefectural Central HospitalActive in the last 2 years

Kunihiro Tsuji

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7463-7272; OpenAlex author ID A5022551435. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: none · 2024: none · 2025: 4 papers

Papers 10

  1. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  2. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  3. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  4. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  5. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  6. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. Co-author DOI 10.1093/jjco/hyac110↗
  7. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
  8. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovaria… Co-author DOI 10.1007/s10147-020-01721-x↗
  9. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-018-3577-9↗
  10. S-1 induced hepatic steatosis in patients with pancreatic cancer: Retrospective analysis. Co-author DOI 10.4251/wjgo.v9.i8.314↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junji Furuse · 8 shared papers, 2018–2025 · strength 1.01
  2. Masafumi Ikeda · 7 shared papers, 2018–2025 · strength 0.90
  3. Makoto Ueno · 7 shared papers, 2018–2025 · strength 0.88
  4. Chigusa Morizane · 6 shared papers, 2020–2025 · strength 0.83
  5. Naohiro Okano · 6 shared papers, 2020–2025 · strength 0.80
  6. Satoshi Kobayashi · 5 shared papers, 2022–2025 · strength 0.72
  7. Takeshi Terashima · 4 shared papers, 2022–2025 · strength 0.64
  8. Yasuyuki Kawamoto · 4 shared papers, 2022–2025 · strength 0.62
  9. Kumiko Umemoto · 4 shared papers, 2022–2025 · strength 0.61
  10. Hiroshi Imaoka · 4 shared papers, 2022–2025 · strength 0.61
  11. Rei Suzuki · 4 shared papers, 2022–2025 · strength 0.54
  12. Akinori Asagi · 4 shared papers, 2020–2025 · strength 0.51
  13. Hiroaki Nagano · 3 shared papers, 2022–2025 · strength 0.43
  14. Yohei Kitano · 3 shared papers, 2022–2025 · strength 0.43
  15. Nobuaki Azemoto · 3 shared papers, 2022–2025 · strength 0.42
  16. Nobumasa Mizuno · 4 shared papers, 2018–2022 · strength 0.39
  17. Masato Ozaka · 3 shared papers, 2018–2025 · strength 0.36
  18. Nana Kimura · 2 shared papers, 2025 · strength 0.32
  19. Masayuki Ueno · 2 shared papers, 2025 · strength 0.32
  20. Toshifumi Doi · 2 shared papers, 2025 · strength 0.32
  21. Reiko Ashida · 2 shared papers, 2025 · strength 0.32
  22. Kohei Nakachi · 2 shared papers, 2025 · strength 0.32
  23. Akihiro Ohba · 2 shared papers, 2025 · strength 0.32
  24. Noritoshi Kobayashi · 2 shared papers, 2025 · strength 0.32
  25. Hiroshi Ohyama · 2 shared papers, 2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.